Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Taysha Gene Therapies, Inc. - Common Stock
(NQ:
TSHA
)
5.430
+0.170 (+3.23%)
Streaming Delayed Price
Updated: 9:34 AM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Taysha Gene Therapies, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Taysha Gene Therapies Inc (NASDAQ:TSHA) Stock Slumps on Q3 Revenue Miss Despite Key Regulatory Win for TSHA-102
↗
November 04, 2025
Taysha Gene Therapies stock fell after Q3 results, with a revenue miss overshadowing positive FDA Breakthrough Therapy designation for its Rett syndrome drug.
Via
Chartmill
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
October 20, 2025
Via
Benzinga
Why Is Taysha Gene Therapies Stock Falling Friday?
↗
October 17, 2025
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.
Via
Benzinga
Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals
↗
October 03, 2025
Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy.
Via
Stocktwits
What's Next: Taysha Gene Therapies's Earnings Preview
↗
August 11, 2025
Via
Benzinga
Where Taysha Gene Therapies Stands With Analysts
↗
June 02, 2025
Via
Benzinga
Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience
October 02, 2025
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Demystifying Taysha Gene Therapies: Insights From 6 Analyst Reviews
↗
October 02, 2025
Via
Benzinga
Discover the most active stocks in Thursday's session.
↗
October 02, 2025
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
October 02, 2025
Via
Benzinga
Here are the top movers in Thursday's session.
↗
October 02, 2025
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday
↗
October 02, 2025
U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.
Via
Benzinga
Topics
Stocks
Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy
↗
October 02, 2025
Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102.
Via
Stocktwits
Which stocks are gapping on Thursday?
↗
October 02, 2025
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via
Chartmill
Top 2 Health Care Stocks That May Keep You Up At Night This Month
↗
October 02, 2025
Via
Benzinga
What's Driving the Market Sentiment Around Taysha Gene Therapies?
↗
September 18, 2025
Via
Benzinga
Is Taysha Gene Therapies Gaining or Losing Market Support?
↗
August 25, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through 11 Analysts
↗
August 13, 2025
Via
Benzinga
Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock
↗
July 01, 2025
Via
Benzinga
Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data
↗
June 03, 2025
Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program.
Via
Stocktwits
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?
↗
May 29, 2025
Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 29, 2025
Via
Benzinga
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
May 28, 2025
Via
Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
↗
May 28, 2025
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 6 Analysts
↗
May 16, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
May 15, 2025
Via
Benzinga
Earnings Scheduled For May 15, 2025
↗
May 15, 2025
Via
Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
↗
May 07, 2025
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
